Scarica l'app Stockscreener
8.98
6.26%
-0.60
Dopo l'orario di chiusura:
8.98
Precedente Chiudi:
$9.58
Aprire:
$9.71
Volume 24 ore:
135.14K
Relative Volume:
0.95
Capitalizzazione di mercato:
$313.25M
Reddito:
$7,000
Utile/perdita netta:
$-41.54M
Rapporto P/E:
-9.6663
EPS:
-0.929
Flusso di cassa netto:
$-20.57M
1 W Prestazione:
-6.36%
1M Prestazione:
-30.28%
6M Prestazione:
-17.77%
1 anno Prestazione:
-34.55%
Intervallo 1D:
$8.92
$9.8761
Intervallo di 1 settimana:
$8.92
$10.17
Portata 52W:
$8.92
$16.76
Benitec Biopharma Inc Stock (BNTC) Company Profile
Nome
Benitec Biopharma Inc
Settore
Industria
Telefono
(510) 780-0819
Indirizzo
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
8.98 | 334.53M | 7,000 | -41.54M | -20.57M | -0.929 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-09-12 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Piper Sandler | Overweight |
| 2020-10-05 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-02-26 | Downgrade | Maxim Group | Buy → Hold |
| 2015-12-31 | Reiterato | Maxim Group | Buy |
| 2015-09-16 | Reiterato | Maxim Group | Buy |
Mostra tutto
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
Benitec Biopharma Ltd ADR (BNTC-Q) Stock Price and News - The Globe and Mail
H.C. Wainwright reiterates Benitec Biopharma stock rating at buy By Investing.com - Investing.com Canada
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC) - Yahoo Finance
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Form 8K Benitec Biopharma Ltd ADR For: 24 September By Investing.com - Investing.com India
Benitec Biopharma appoints Ernst & Young as new auditor, replaces Baker Tilly - Investing.com
An auditor in place since 2020 is out at Benitec Biopharma (BNTC). Ernst & Young is named, pending acceptance. - Stock Titan
Benitec Biopharma FY 2026 Earnings: Revenue Flat at $0, Net Loss Widens to $45.5 Million - Sci-Tech Today
Benitec Biopharma Inc. Share PriceBNTC, RNS News, Articles, Quotes, & Charts (NASDAQ:BNTC) - Proactive financial news
Evercore Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
BENITEC BIOPHARMA Q4 2026 Earnings Preview: Recent $BNTC Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Benitec Biopharma (NASDAQ: BNTC) Reports $180M Cash Reserves as BB-301 Trial Progresses Toward 2027 Milestone - kalkinemedia.com
BNTC Maintains by Wedbush -- Price Target Raised to $17.00 - GuruFocus
Wedbush Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating - Yahoo Finance
Avoiding Lag: Real-Time Signals in (BNTC) Movement - Stock Traders Daily
Benitec Biopharma Files $200 Million Shelf Registration - marketscreener.com
Benitec (NASDAQ: BNTC) prepares $200M shelf that may back its lead gene therapy - Stock Titan
Benitec Biopharma Inc. FY 2026: Revenue $0 EPS $(0.98) — 10-K Summary - TradingView
Live Benitec Biopharma Inc. (BNTC) Technical Analysis - Traders Union
Benitec Biopharma reports FY2026 net loss $45.5M, cash $180.0M; advances BB-301 clinical program - tradingview.com
Benitec Reports $45.5 Million Full-Year Loss as BB-301 Trial Advances - Quiver Quantitative
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update - GlobeNewswire
Benitec Biopharma Inc.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
(BNTC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Enterprise value to revenue forward of Benitec Biopharma Inc. – NASDAQ:BNTC - TradingView
Benitec (BNTC) Trading: Moves 5.71% Lower to $12.71 for the Current Session; Next Session: the $12.07 to $13.35 Range Remains in Focus in the Latest ReadingBuffered ETF - vinanet.vn
Benitec (BNTC) Levels: Posts a 4.33% Loss to $12.80 in the Latest Session; Current Setup: Price Remains Between $12.16 Support and $13.44 Resistance at the CloseVolume Spike Alerts - vinanet.vn
Benitec (BNTC) Earnings Update: The EPS Result Is Above Expectation for the Current Session; Price Reaction: The Market Price Advances 3.88% in the Latest ReadingDividend Earnings Report - dars.gov.et
Benitec (BNTC) EPS and Revenue: EPS Beats Its Estimate in Latest Trading; Latest Reaction: Shares Close 1.45% Lower on the DayPeak Earnings Alert - vinanet.vn
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Trading Systems Reacting to (BNTC) Volatility - Stock Traders Daily
BNTC Q2 2026 Earnings: Loss Narrows More Than Expected as EPS Beats Estimates by 14%Profit Guidance Range - vinanet.vn
Benitec Biopharma (BNTC) Advances 3% as Shares Test Key Resistance LevelUnusual Call Volume - Vinanet
BNTC Q2 2026 Earnings: EPS Beats Estimates Despite Revenue Absence and Share DeclineBook Value Growth - dars.gov.et
Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Above 50 Day Moving AverageTime to Sell? - marketbeat.com
Benitec Biopharma Inc (BNTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth - moomoo.com
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Sahm
How Benitec Biopharma Inc. (BNTC) Affects Rotational Strategy Timing - Stock Traders Daily
Benitec Biopharma (BNTC) Slips 1.26% as Shares Test Key Support at $11.12Factor Crowding - dars.gov.et
Benitec Biopharma (NASDAQ:BNTC) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Benitec Biopharma Inc (BNTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BNTC Initiated by Wedbush -- Rating Set to Outperform with PT at $16.00 - GuruFocus
Wedbush Initiates Coverage on Benitec Biopharma (BNTC) with Outp - GuruFocus
Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target - Yahoo Finance
Benitec Biopharma Inc (BNTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Benitec Biopharma Inc (BNTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BNTC|Benitec Biopharma Inc|Price:11.710|Chg%:+0.240 - TradingKey
Benitec Biopharma Inc (BNTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BNTC|Benitec Biopharma Inc|Price:11.540|Chg%:+0.070 - TradingKey
Benitec Biopharma Inc Azioni (BNTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Benitec Biopharma Inc Azioni (BNTC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):